Drugs / FOLFOX
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT06179160 Background | Jan 2024 → Jan 2027 expected | cancer | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01047293 Background | May 2010 → Aug 2015 | colorectal cancer | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT04162665 Background | Feb 2020 → Dec 2023 | gastric adenocarcinoma | Washington University School of Medicine | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FOLFOX | “The recommendations are CAPOX, FOLFOX, or FLT.” NCT04162665 ↗ |
| Known as | 5-FU | “5-FU is an anti-metabolite that blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, causing thymidine-less cell death in rapidly growing cells.” NCT01047293 ↗ |
| Action | Inhibit | “5-FU is an anti-metabolite that blocks the methylation reaction of deoxyuridylic acid to thymidylic acid” NCT01047293 ↗ |
| Route | Intravenous | “oxaliplatin 85 mg/m2 IV with LV 350 mg IV over 2 hours plus FU 400 mg/m2 IV bolus and 2,400 mg/m2continuous infusion over 46 hours every 2 weeks” NCT01047293 ↗ |